Last reviewed · How we verify
NCT03617796: CD64
Prognostic Value of CD64 Marker for Patients in Intensive Care Unit
trial in Systemic Inflammatory Response Syndrome in 100 participants. Status unknown.
9 December 2018
Quick facts
| Lead sponsor | Central Hospital, Nancy, France |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 10 September 2018 |
| Primary completion | 9 December 2018 |
| Estimated completion | 31 December 2018 |
| Sites | 1 location across France |
Conditions studied
- Systemic Inflammatory Response Syndrome — all drugs for Systemic Inflammatory Response Syndrome →
- Intensive Care — all drugs for Intensive Care →
Sponsor
Central Hospital, Nancy, France
Who can join
18 and older, any sex, with Systemic Inflammatory Response Syndrome or Intensive Care. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Among patients admitted to the intensive care unit (ICU), early recognition of those with the highest risk of death is of paramount importance. Since clinical judgment is sometimes uncertain biomarkers could provide additional information likely to guide critical illness management. We want to evaluate the prognostic value of leucocyte surface expression of CD64. Blood samples for CD64 biomarker measurement will be obtained daily during the patient's hospitalization. The primary outcome was all-cause death at D28 after admission
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03617796
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Systemic Inflammatory Response Syndrome
Currently open trials in the same condition.
- NCT06195267 — Protective Effect of Sivelestat Against Negative Pulmonary Function and Organ Dysfunction After Cardiovascular Surgery ( · NA · recruiting
- NCT05969275 — Umbilical Mesenchymal Stromal Cells as Cellular Immunotherapy for Septic Shock · Phase 2 · recruiting
- NCT06052436 — Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Control the Immune Hyperactivation Associated With · Phase 1, PHASE2 · recruiting
- NCT05663216 — Determinants of Vascular Leakage During Systemic Inflammatory Response Syndrome · recruiting
- NCT06028789 — AOrtic Surgery: Systemic Inflammatory Response Versus Sepsis · recruiting
Other Central Hospital, Nancy, France trials
Trials by the same sponsor.
- NCT06452290 — PET Biomarker Study for Antidepressant Response Prediction in Major Depressive Disorder · NA · not yet recruiting
- NCT07518498 — Hypnosis During Mechanical Ventilation Weaning · NA · not yet recruiting
- NCT07471334 — Prospective Study of Postictal Psychotic Symptoms Occuring After Video-EEG Monitoring in Focal Epilepsies · NA · not yet recruiting
- NCT07414667 — Primary Sjögren's Syndrome: Impact of Quantitative Anti-Ro52 Antibody Analysis on Patient Prognosis and Stratification ( · not yet recruiting
- NCT07415759 — Imaging of Electrical Properties by MRI: Investigation of Age-Related Changes · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03617796 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Central Hospital, Nancy, France
- Last refreshed: 6 August 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03617796.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing